Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Stephen Hagan

Pulmonary Disease Wichita, KS Medical Doctor

NPI 1376569616 CMS profile 244251

1035 N Emporia St, Ste 102, Wichita, KS 67214

Open in the dashboard

General payments

$2,894

178 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Stephen Hagan of Wichita, KS is reported in the CMS Open Payments database as having received $2,894 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $311 8
2022 General $887 53
2021 General $734 47
2020 General $394 27
2019 General $568 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Hagan
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Stephen Hagan were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Stephen Hagan Pulmonary Disease median Middle half National median
2019 $568 $377 $109–$1,340 $163
2020 $394 $230 $56–$907 $114
2021 $734 $269 $68–$1,072 $132
2022 $887 $390 $100–$1,457 $149
2023 $311 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $549 36 payments
  2. GlaxoSmithKline, LLC. $535 41 payments
  3. Mylan Specialty L.P. $367 26 payments
  4. Actelion Pharmaceuticals US, Inc. $336 16 payments
  5. United Therapeutics Corporation $223 13 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $200 1 payment
  7. Novartis Pharmaceuticals Corporation $146 11 payments
  8. Grifols USA, LLC $141 8 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $67 4 payments
  10. Sunovion Pharmaceuticals Inc. $55 4 payments
  11. Other $276 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,614 176 payments
  2. Consulting Fee $200 1 payment
  3. Education $80 1 payment
Products named General payments · program years 2019–2023
  1. BREZTRI $340 20 payments
  2. TRELEGY ELLIPTA $338 25 payments
  3. OPSUMIT $294 14 payments
  4. UPTRAVI $232 9 payments
  5. Adempas $200 1 payment
  6. Yupelri Respiratory and Allergy $199 15 payments
  7. Perforomist $197 15 payments
  8. FARXIGA $158 9 payments
  9. YUPELRI Anticholinergics, Inhaled $153 10 payments
  10. XOLAIR $146 11 payments
  11. Other $1,208 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record